ArticleInfluenza and other respiratory viruses2021
Comparative incidence and burden of respiratory viruses associated with hospitalization in adults in New York City.
Article in Influenza and other respiratory viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Global Burden of Human Metapneumovirus in High-Risk Adults: A Systematic Literature Review and Meta-Analysis.Journal of epidemiology and global health · 2026Pooled it
- Global Epidemiology and Disease Burden of Human Parainfluenza Virus in Adults: A Systematic Review.Reviews in medical virology · 2026Pooled it
- Incidence, Complications, and Quality of Life in Adults ≥ 60 Years Old With Laboratory-Confirmed RSV Infections Attended in Primary Care and in Hospitals: A Study Over Three Seasons in Valladolid, Spain.Influenza and other respiratory viruses · 2026Observational
- Characteristics and Risk Factors Associated With Hospitalization and Severe Disease in Patients Aged ≥ 60 Years With Human Metapneumovirus Infection Over Three Consecutive Seasons (2021-2024) in Valladolid, Spain. The VALLAVIRUS Study.Influenza and other respiratory viruses · 2026Article
- Clinical Characteristics and Severity of Rhinovirus/Enterovirus-Associated Hospitalizations: A Multicountry Analysis From the Global Influenza Hospital Surveillance Network, 2017-2024.Open forum infectious diseases · 2026Article
- Comparison of Hospitalization Costs Associated With Human Metapneumovirus and Respiratory Syncytial Virus Infection in US Adults.Open forum infectious diseases · 2026Article
- Comparison of Healthcare Resource Utilization and Disease Outcomes in Adults Hospitalized with Human Metapneumovirus and Respiratory Syncytial Virus.The Journal of infectious diseases · 2026Article
- Article
- Recent developments of vaccines for older adults: Adjuvants and beyond.Human vaccines & immunotherapeutics · 2025Review
- Pre-COVID-19 epidemiology of community respiratory viruses at a single US center reveals sex differences in influenza A and a higher ICU incidence of human metapneumovirus in the elderly population.BMC infectious diseases · 2025Article
- A Randomized Phase 1 Clinical Trial of a Respiratory Syncytial Virus and Human Metapneumovirus Combination Protein-Based Virus-like Particle Vaccine in Adults 60-75 Years of Age.Open forum infectious diseases · 2025Article
- Incidence of RSV in Adults: A Comprehensive Review of Observational Studies and Critical Gaps in Information.The Journal of infectious diseases · 2024Review
- Efficacious human metapneumovirus vaccine based on AI-guided engineering of a closed prefusion trimer.Nature communications · 2024Article
- Cross-protective antibodies against common endemic respiratory viruses.Nature communications · 2023Article
- Cost of lost productivity from acute respiratory infections in South America.Revista panamericana de salud publica = Pan American journal of public health · 2023Article
- Estimating the burden of adult hospitalized RSV infection using local and state data - methodology.Human vaccines & immunotherapeutics · 2022Article
- Risk factors and medical resource utilization in US adults hospitalized with influenza or respiratory syncytial virus in the Hospitalized Acute Respiratory Tract Infection study.Influenza and other respiratory viruses · 2022Article
- Estimating the burden of adult hospitalized RSV infection including special populations.Vaccine · 2022Article
- Risk Factors and Medical Resource Utilization of Respiratory Syncytial Virus, Human Metapneumovirus, and Influenza-Related Hospitalizations in Adults-A Global Study During the 2017-2019 Epidemic Seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study).Open forum infectious diseases · 2021Article
- Comparative incidence and burden of respiratory viruses associated with hospitalization in adults in New York City.Influenza and other respiratory viruses · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough the burden of influenza is well characterized, the burden of community-onset non-influenza respiratory viruses has not been systematically assessed. Understanding the severity and seasonality of non-influenza viruses, including human coronaviruses, will provide a better understanding of the overall disease burden from respiratory viruses that could better inform resource utilization for hospitals and highlight the value of preventative strategies, including vaccines.
methodsFrom October 2017 to September 2019, a retrospective study was performed in a pre-defined catchment area to estimate the population-based incidence of community-onset respiratory viruses associated with hospitalization. Included patients were ≥18 years old, resided in New York City, were hospitalized for ≥24 hours, and had a respiratory virus detected within 3 calendar-days of admission. Disease burden was measured by hospital length of stay (LOS), intensive care unit (ICU) admissions, and in-hospital mortality and compared among those with laboratory-confirmed influenza versus those with laboratory-confirmed non-influenza viruses (human coronaviruses, parainfluenza viruses, respiratory syncytial virus, human metapneumovirus, and adenovirus).
resultsDuring the study period, 4232 eligible patients were identified of whom 50.9% were ≥65 years of age. For each virus, the population-based incidence was highest for those ≥80 years of age. When compared to those with influenza viruses detected, those with non-influenza respiratory viruses detected (combined) had higher population-based incidence, significantly more ICU admissions, and higher in-house mortality.
conclusionsThe burden of non-influenza respiratory viruses for hospitalized adults is substantial. Prevention and treatment strategies are needed for non-influenza respiratory viruses, particularly for older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.